Rapamycin, the mTOR inhibitor, was able to decrease the IL-8 expression, thus decrease the resistance to sorafenib.260 A neutralizing antibody, HuMAX-IL8, was used to deplete IL-8 secretion and treat human TNBC.261 Another study showed that neutralizing IL-8 can alleviate resistance to erlotinib in NSCLC, thereby enhancing sensitivity in chemotherapy-resistant cells.262 Inhibition of CXCR2 with SB225002 also alleviated the IL-8-related resistance in sorafenib-resistant ovarian tumor cells.263. This evidence concerns the gene CXCL8 and ovarian neoplasm.